Cargando…

P15-18. Behavioral and social science in HIV vaccine clinical research: workshop recommendations

Detalles Bibliográficos
Autores principales:	Lau, C, Swann, EM, Gaist, P, Allen, MA
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767714/ http://dx.doi.org/10.1186/1742-4690-6-S3-P219

Ejemplares similares

Applying the Behavioural and Social Sciences Research (BSSR) Functional Framework to HIV Cure Research
por: Dubé, Karine, et al.
Publicado: (2019)

P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation
por: Sitar, S, et al.
Publicado: (2009)

P15-26. Leveraging motivators to participation in HIV vaccine research in the age of Obama
por: Alexander, SB, et al.
Publicado: (2009)

P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2009)

Risk of weaning failure with PAOP ≥15 versus PAOP ≥18
por: Nassar, Y, et al.
Publicado: (2013)

P15-28. Attitudes and awareness of HIV vaccine research in HIV uninfected MSM in four US cities: Rochester, Boston, San Francisco and Philadelphia
por: Alexander, SB, et al.
Publicado: (2009)

Social and contextual factors that influence HIV risk behaviors among indigenous MSM in the Peruvian Amazon
por: Alva, Isaac E, et al.
Publicado: (2012)

P15-03. HIV vaccine funding trends entering a global recession: research and development (R&D) from 2000 – 2008
por: Fisher, K, et al.
Publicado: (2009)

Therapeutics designed to neutralize soluble HIV tat protein could preserve IL-7 signaling and CD8 T-cell function in HIV+ patients
por: Faller, EM, et al.
Publicado: (2010)

Developing a framework for replication of research in implementation science
por: Curran, Janet, et al.
Publicado: (2014)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

HIV-associated bladder cancer: diagnosis and management
por: Pantanowitz, L, et al.
Publicado: (2009)

P15-10. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand
por: Newman, PA, et al.
Publicado: (2009)

P15-23. Community engagement strategies in the Canadian HIV vaccine initiative
por: Milsom, P, et al.
Publicado: (2009)

P15-27. Community involvement and ethics in HIV vaccine trial in Nigeria
por: Adeyemi, AO, et al.
Publicado: (2009)

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
por: Scarlatti, G, et al.
Publicado: (2009)

Anal and cervical cytologic abnormalities among HIV-infected women in the era of HAART
por: Kojic, EM, et al.
Publicado: (2009)

P18-13 LB. Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals
por: Yassine Diab, B, et al.
Publicado: (2009)

P05.15. Online indexing service for research articles published on Ayurveda
por: Manohar, R, et al.
Publicado: (2012)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
por: Zembe, L, et al.
Publicado: (2012)

P06-09. Web based interviewing system for HIV-behavior research in the settings of vaccine and non vaccine prevention trials
por: Peinado, JE, et al.
Publicado: (2009)

P18-03. Dendritic cell-based immune therapy against HIV-1
por: Gruters, RA, et al.
Publicado: (2009)

Stigma and HIV risk behaviors of transgender women in Nepal: implications for HIV prevention
por: Wilson, Erin, et al.
Publicado: (2010)

P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research
por: Mark, D, et al.
Publicado: (2009)

P15-11. Preventive HIV vaccine acceptability: a systematic review and meta-analysis
por: Newman, PA, et al.
Publicado: (2009)

P15-20. Developing a national policy agenda for the Canadian HIV vaccine initiative
por: Sarazin, V, et al.
Publicado: (2009)

P15-22. Potential synergies between HIV vaccines, microbicides and pre-exposure prophylaxis
por: Sarazin, V, et al.
Publicado: (2009)

HIV patients admitted to an ICU of a university hospital - experience of 15 years: 1995 to 2009
por: Agrifoglio, A, et al.
Publicado: (2013)

Setting up a clinical trial in care homes: challenges encountered and recommendations for future research practice
por: Shepherd, Victoria, et al.
Publicado: (2015)

The evaluation of peer education workshops efficacy on knowledge of non medical students about HIV/AIDS, Bushehr, South of Iran
por: Maneshi, Hesam_oddin, et al.
Publicado: (2010)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

P15-16. Social factors affecting retention rates in Step study participants in Lima-Peru
por: Fernandez-Maldonado, MD, et al.
Publicado: (2009)

Pap testing among newly diagnosed women living with HIV/AIDS (WLWHA) in South Carolina (SC): routine screening and abnormal follow-up behaviors of HIV-positive female SC medicaid recipients 18-64 years between 2005-2009
por: Wigfall, Lisa T, et al.
Publicado: (2012)

RNA remarkably promotes HIV-1 protease fast turnover for NCp15 processing in mild acidic conditions leading to condensation of HIV-1 nucleocapsid
por: Lyonnais, Sebastien, et al.
Publicado: (2013)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
por: Koblin, B, et al.
Publicado: (2012)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

P16-18. Regulatory T cell frequencies correlate with T cell activation in chronic HIV-1 infection
por: Angin, M, et al.
Publicado: (2009)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
por: Allen, MA, et al.
Publicado: (2009)

P15-21. Investigating the utility and relevance of the good participatory practice guidelines for biomedical HIV prevention trials
por: Miller, L, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qg759hehiojitjob7hkdht3926